Newron Pharmaceuticals Spa Stock Earnings Reports

Newron reported strong progress across clinical, corporate and financial fronts. Key clinical developments: initiation and active enrollment of three pivotal Phase III programs for evenamide (ENIGMA-TRS1: 600-patient 52-week TRS study; ENIGMA-TRS2: 400–600 patient 12-week study; plus Eisai’s parallel Phase III), representing >1,300 patients worldwide; expectation of 12-week readouts (primary endpoint) within the year and top-line TRS1 results by year-end. Clinical data highlighted: positive 1-year open-label TRS results, a statistically significant Phase III 4-week study (8A) with PANSS primary endpoint (p=0.006), favorable tolerability (most common AE nasopharyngitis), and preclinical evidence (University of Pittsburgh) suggesting hippocampal mechanism and durable effects beyond drug exposure, supporting benefits on negative symptoms and cognition. IP and regulatory: European grant of a crystalline-form composition patent with a pending U.S. prosecution that—if granted—could extend exclusivity to 2044 (≈17 years post expected approval). Corporate/financials: December 2024 Eisai deal brought EUR 48m to fund pivotal work; additional funding agreement provides up to EUR 38m (EUR 15m already received, EUR 11m expected within the year, EUR 12m conditional on positive pivotal results) and EIB loan repayment delayed to June 2028—together expected to fund the company through the 12-week readouts and enable NDA preparation. Corporate actions: proposed 15% capital authorization and potential uplisting/ADR groundwork to facilitate future U.S. listing and institutional investor build-out. Management emphasized exploration of additional indications (bipolar disorder, treatment-resistant depression with psychosis, dementia-related behavioral symptoms) and longer-term formulation opportunities (long-acting injectables) post-NDA.